Exchange Traded Concepts LLC Has $115,000 Stake in Immatics N.V. (NASDAQ:IMTX)

Exchange Traded Concepts LLC boosted its holdings in Immatics N.V. (NASDAQ:IMTX) by 94.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,580 shares of the company’s stock after purchasing an additional 12,425 shares during the period. Exchange Traded Concepts LLC’s holdings in Immatics were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of America Corp DE grew its position in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Virtus ETF Advisers LLC raised its stake in Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock worth $68,000 after purchasing an additional 2,479 shares in the last quarter. Intellectus Partners LLC acquired a new position in shares of Immatics in the 1st quarter valued at approximately $70,000. Guggenheim Capital LLC acquired a new position in shares of Immatics in the 4th quarter valued at approximately $101,000. Finally, Forefront Analytics LLC raised its position in shares of Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company’s stock valued at $113,000 after buying an additional 4,731 shares in the last quarter. Institutional investors own 64.41% of the company’s stock.

Immatics Stock Up 0.4%

IMTX opened at $5.44 on Wednesday. The stock has a market cap of $661.23 million, a PE ratio of -32.00 and a beta of 0.83. Immatics N.V. has a 52 week low of $3.30 and a 52 week high of $13.09. The business’s fifty day simple moving average is $5.15 and its 200 day simple moving average is $5.33.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 14.73% and a negative return on equity of 4.52%. The business had revenue of $20.12 million during the quarter, compared to analyst estimates of $14.92 million. As a group, equities analysts anticipate that Immatics N.V. will post -0.72 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Immatics from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a research note on Tuesday, April 1st. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immatics in a research report on Wednesday, May 28th. They set a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Immatics currently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.